Georgia Cancer Specialists’ stature as an oncology practice of national importance was recognized by an appearance in The New York Times recently.
Georgia Cancer Specialists is the only oncology practice mentioned in the story and Dr. Bruce Feinberg appears in the story as president of Georgia Cancer Specialists. He was interviewed at length on two occasions approximately six months apart.
The article, written by Andrew Pollack, focused on Erbitux, a drug that had been studied in clinical trials for its effect on colon cancer. The Food and Drug Administration, citing deficiencies in the clinical trials, recently refused to review ImClone’s application to sell the drug.
Some cancer patients are frustrated with the delay and blame the FDA and pharmaceutical companies. ImClone and Bristol-Myers Squibb said they would soon begin several clinical trials aimed at winning approval for Erbitux.
“By the end of the year, they hope to begin a program to provide the drug to desperately ill cancer patients who are not in the trial,” writes Pollack.